HOME >> MEDICINE >> NEWS
Possible treatment found for 'chemobrain'

Patients who take medication for cancer often find themselves with a new problem when their treatment ends.

It's called "chemobrain," a common consequence of chemotherapy that causes memory problems, confusion and difficulty in concentrating.

Symptoms of chemobrain can also include lack of focus, inability to organize daily activities, mental confusion, memory loss and decreased mental clarity.

It's estimated that chemobrain occurs in as many as 99 percent of breast and ovarian cancer patients receiving chemotherapy or radiation treatments. Sixty-one percent of these patients continue to experience fatigue and memory problems long after their cancer treatment has stopped.

Now, researchers led by the University of Cincinnati's (UC) Elyse Lower, MD, report a possible new treatment for the problem using the drug dexmethyphenidate (d-MPH).

Dr. Lower, professor of hematology/oncology at UC College of Medicine, recently described the encouraging results of a 14-month, multi-center, Phase 2 study of d-MPH to the annual meeting of the American Society of Clinical Oncology.

The 154 cancer survivors at 21 medical centers showed significant reduction in fatigue and improvement in memory when treated with dosages of 10 mg to 50 mg of d-MPH per day, Dr. Lower said, when compared with a control group receiving a placebo.

All the patients, who had a median age of 53 years, had completed at least four cycles of chemotherapy at least two months before the study began. Ninety percent of them were female (76 percent with breast cancer and 14 percent with ovarian cancer), 79 percent were white and 9 percent were African-American.

"The study showed that up to 50 mg a day of d-MPH is safe and effective for relieving chemobrain in adult cancer patients," said Dr. Lower, "and it should be considered as a treatment."

One of the study participants, Marilyn Metz, had undergone radiation and chemotherapy in 2001 to t
'"/>

Contact: Sheryl Hilton
sheryl.hilton@uc.edu
513-558-4561
University of Cincinnati
7-Jun-2005


Page: 1 2

Related medicine news :

1. Possible new breast cancer gene
2. Possible predictors of relationship violence
3. Possible exposure to nerve agents and brain cancer deaths in Gulf War veterans
4. Spot on treatment for acne
5. New treatment boosts muscle function in myasthenia gravis
6. New treatment effective in counteracting cocaine-induced symptoms
7. UCLA researchers awarded $9M contract for study identifiying antibiotic treatment for MRSA
8. Preventive treatments in elderly people needs rethinking
9. Osteoporosis screening and treatment may be cost-effective for selected older men
10. Quality of treatment guidelines
11. Green tea holds promise as new treatment for inflammatory skin diseases

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Possible treatment found for chemobrain

(Date:10/30/2014)... By Dennis Thompson ... -- Drinking lots of milk could be bad for your ... that the calcium in milk can help strengthen bones and ... health officials to recommend milk as part of a healthy ... amounts of milk did not protect men or women from ...
(Date:10/30/2014)... 29, 2014 (HealthDay News) -- Eating a low-carb, high-fat ... treat, according to new research. A review ... Atkins diet, that focuses on foods like bacon, eggs, ... reduce seizures in adults whose condition doesn,t improve with ... percent of people with epilepsy whose seizures are not ...
(Date:10/30/2014)... new vaccine that could help prevent some cases of ... Food and Drug Administration on Wednesday. Trumenba is ... and 25 from invasive meningococcal disease caused by ... can infect the bloodstream (sepsis) and the lining that ... leading cause of bacterial meningitis, and infection can occur ...
(Date:10/30/2014)... standard of care for children facing acute myeloid leukemia ... in the latest edition of the New England ... John Wagner, Jr., M.D., director of the Pediatric Blood ... and a researcher in the Masonic Cancer Center, University ... and myelodysplastic syndrome who received transplants of either one ...
(Date:10/29/2014)... 2014 – Many of the women at first acted surprised. ... to researchers why they had not used the study products ... prevention trial that, as a likely consequence, did not find ... effective. , The women were among 127 former VOICE ... D, agreed to take part in in-depth interviews and/or focus ...
Breaking Medicine News(10 mins):Health News:Is Milk Your Friend or Foe? 2Health News:Is Milk Your Friend or Foe? 3Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 2Health News:High-Fat, Low-Carb Diet May Help With Tough-to-Treat Epilepsy 3Health News:FDA Approves New Vaccine to Protect Against Meningitis 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 2Health News:Survival rates in pediatric umbilical cord transplants may indicate a new standard of care 3Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 2Health News:Women who took part in VOICE speak up about why they didn't use HIV prevention products 3
(Date:10/30/2014)... -- Zimmer Holdings, Inc. (NYSE: ZMH and ... and organizational structure of the combined company following the ... the combined organization will leverage the strength of both ... the new brand to be rolled out across the ... future leadership team is committed to establishing Zimmer Biomet ...
(Date:10/30/2014)... Oct. 30, 2014   ViaDerma, Inc. ... bringing new products to market, has recently released ... TetraStem is a topical liquid tetracycline-based antibiotic that ... can convert oral medication active ingredients into topical ... first aid antibiotic to help prevent skin infection ...
(Date:10/30/2014)... SAN FRANCISCO , Oct. 30, 2014  Nektar ... financial results for the third quarter ended September 30, ... of U.S.-based financial markets. Howard Robin , president ... to review the results beginning at 5:00 p.m. Eastern ... The press release and a live audio-only Webcast of ...
Breaking Medicine Technology:Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 2Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 3Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 4Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 5Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 6Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 7Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 8Zimmer Announces Executive Leadership Team and New Name of Combined Company Following Closing 9ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 2ViaDerma, Inc. Lead Product TetraStem Shown Effective in Fighting Staph Infections including MRSA 3Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
Cached News: